Stifel Downgrades Surgery Partners (SGRY) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Surgery Partners (SGRY) PT Lowered to $17 at Citi
August 11, 2017 8:42 AM EDTCiti lowered its price target on Surgery Partners (NASDAQ: SGRY) to $17.00 (from $28.00) while maintaining a Buy rating.
... MoreRaymond James Downgrades Surgery Partners (SGRY) to Market Perform
August 9, 2017 3:52 AM EDTRaymond James downgraded Surgery Partners (NASDAQ: SGRY) from Strong Buy to Market Perform.
For an analyst ratings summary and ratings history on Surgery Partners click here. For more ratings news on Surgery Partners click here.
Shares of Surgery Partners closed at $19.15 yesterday.
... MoreKeyBanc Downgrades Surgery Partners (SGRY) to Sector Weight
August 9, 2017 3:45 AM EDTKeyBanc downgraded Surgery Partners (NASDAQ: SGRY) from Overweight to Sector Weight.
For an analyst ratings summary and ratings history on Surgery Partners click here. For more ratings news on Surgery Partners click here.
Shares of Surgery Partners closed at $19.15 yesterday.
... MoreSurgery Partners, Inc. (SGRY) Misses Q2 EPS by 27c, Miss on Revenues; Offers FY17 Revenues
August 8, 2017 4:15 PM EDTSurgery Partners, Inc. (NASDAQ: SGRY) reported Q2 EPS of ($0.09), $0.27 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $288.4 million versus the consensus estimate of $314.22 million.
Full Year 2017 Guidance
For 2017, the Company is modifying the guidance provided on our conference call in March... More
